Ikena Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	3.85	9.16	15.62	30.99	9.19	13.75
Revenue Growth (YoY)	-78.07%	-41.35%	-49.59%	237.01%	-33.15%	-
Gross Profit	3.85	9.16	15.62	30.99	9.19	13.75
Selling, General & Admin	25.65	24.93	22.2	18.02	8.87	7.31
Research & Development	53.75	59.65	64.32	47.11	44.85	24.94
Other Operating Expenses	2.58	0	0	0	0	0
Operating Expenses	81.98	84.58	86.52	65.12	53.71	32.25
Operating Income	-78.13	-75.42	-70.9	-34.14	-44.52	-18.49
Other Expense / Income	-7.9	-7.09	-2.14	-0.02	-0.26	-1.68
Pretax Income	-70.23	-68.33	-68.77	-34.12	-44.26	-16.82
Income Tax	-0.14	-0.16	0	0	0	0
Net Income	-70.09	-68.17	-68.77	-34.12	-44.26	-16.82
Shares Outstanding (Basic)	48	42	36	28	3	3
Shares Outstanding (Diluted)	48	42	36	28	3	3
Shares Change	33.10%	15.33%	29.32%	911.88%	4.43%	-
EPS (Basic)	-1.57	-1.63	-1.90	-1.22	-16.00	-6.35
EPS (Diluted)	-1.57	-1.63	-1.90	-1.22	-16.00	-6.35
Free Cash Flow	-78.47	-80.16	-75.54	-62.01	-38.59	47.61
Free Cash Flow Per Share	-1.63	-1.92	-2.09	-2.22	-13.96	17.98
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-2030.33%	-823.33%	-453.99%	-110.18%	-484.22%	-134.46%
Profit Margin	-1821.54%	-744.17%	-440.29%	-110.10%	-481.36%	-122.28%
Free Cash Flow Margin	-2039.11%	-875.08%	-483.67%	-200.14%	-419.75%	346.19%
EBITDA	-67.4	-65.59	-66.73	-32.4	-42.99	-16.7
EBITDA Margin	-1751.51%	-716.09%	-427.27%	-104.56%	-467.61%	-121.39%
Depreciation & Amortization	2.83	2.73	2.03	1.72	1.26	0.12
EBIT	-70.23	-68.33	-68.77	-34.12	-44.26	-16.82
EBIT Margin	-1825.05%	-745.94%	-440.29%	-110.10%	-481.36%	-122.28%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).